The First Test: What Exactly Did the Court Approve?

The 23andMe case can now be stated in one sentence, but only if the sentence keeps the asset boundary and the transaction structure intact: the bankruptcy estate transferred its business-held interests, including interests connected to genetic data, into Newco; TTAM acquired Newco; the same testing business and much of the same access structure were meant to continue; and customer rights and privacy rules remained relevant. This checkpoint connects those facts to a practical judgment. It separates what the court approved from what the states and the Consumer Privacy Ombudsman argued, then identifies the factual questions that must be answered before applying any legal rule.

One transaction, stated without the shorthand

The debtors operated a direct-to-consumer genetic-testing business. Their customer-related holdings included saliva samples, genetic results, account information, and research relationships. The court did not treat those items as a free-floating commodity, but it did treat them as part of a business asset package that could have substantial value in a bankruptcy sale.

Under the Equity Toggle, a wholly owned subsidiary called Newco would receive the debtors’ assets, including customer data, in exchange for a promissory note. The debtors would then sell all of Newco’s equity to TTAM Research Institute. TTAM would own the subsidiary that housed the data and other assets. Existing employees and subcontractors were expected to remain, and the transaction did not anticipate giving genetic-data access to people who lacked it before closing.

The transaction therefore changed something real: the estate’s interest in the operating business and the corporate entity controlling it. It did not follow that every customer right changed with it. Customers could delete accounts, direct disposal of saliva samples, and opt out of research. The court’s discussion of Texas law treated a customer’s recognized property interest in a sample or test result as remaining with the customer, not as something the estate could sell away.

That single paragraph contains the central distinction. The estate’s transferable interest was broad enough to support a going-concern sale, but not so broad that the word asset erased the customer’s relationship or made future use irrelevant. “The data was sold” is therefore a description of a transaction with missing terms. To judge it, one must ask what interest was transferred, to whom, for what purpose, with what access, and subject to which controls.

The court approved a structure, not an unrestricted permission

The court approved the proposed sale after considering the business value, the operational continuity, the privacy enhancements, and the alternatives. It did not approve a general proposition that any company in bankruptcy may transfer genetic information as though it were office furniture.

The court’s positive findings were transaction-specific. TTAM would operate essentially the same business, retain the same employees, and use the same basic privacy policy, while adding protections.